Literature DB >> 16842969

Ligand-specific receptor states: implications for opiate receptor signalling and regulation.

Graciela Piñeyro1, Elodie Archer-Lahlou.   

Abstract

Opiate drugs produce their effects by acting upon G protein coupled receptors (GPCRs) and although they are among the most effective analgesics available, their clinical use is restricted by unwanted side effects such as tolerance, physical dependence, respiratory depression, nausea and constipation. As a class, opiates share a common profile of unwanted effects but there are also significant differences in ligand liability for producing these actions. A growing number of studies show that GPCRs may exist in multiple active states that differ in their signalling and regulatory properties and which may distinctively bind different agonists. In this review we summarize evidence supporting the existence of multiple active conformations for MORs and DORs, analyze information favouring the existence of ligand-specific receptor states and assess how ligand-selective efficacy may contribute to the production of longer lasting, better tolerated opiate analgesics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842969     DOI: 10.1016/j.cellsig.2006.05.026

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  25 in total

1.  Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists.

Authors:  Iness Charfi; Karim Nagi; Ouissame Mnie-Filali; Dominic Thibault; Gianfranco Balboni; Peter W Schiller; Louis-Eric Trudeau; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

2.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

3.  Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones.

Authors:  Alex Straiker; Jim Wager-Miller; Jacqueline Hutchens; Ken Mackie
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins.

Authors:  Nicolas Audet; Céline Galés; Elodie Archer-Lahlou; Marc Vallières; Peter W Schiller; Michel Bouvier; Graciela Pineyro
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

Review 5.  In search of analgesia: emerging roles of GPCRs in pain.

Authors:  Laura S Stone; Derek C Molliver
Journal:  Mol Interv       Date:  2009-10

6.  A "tail" of opioid receptor variants.

Authors:  Stephanie Puig; Howard B Gutstein
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

7.  Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.

Authors:  Ashish K Rehni; Nirmal Singh; Mahesh Rachamalla; Kulbhushan Tikoo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-25       Impact factor: 3.000

8.  Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Cocaine dysregulates opioid gating of GABA neurotransmission in the ventral pallidum.

Authors:  Yonatan M Kupchik; Michael D Scofield; Kenner C Rice; Kejun Cheng; Bernard P Roques; Peter W Kalivas
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.